Vericel (NASDAQ:VCEL) has earned an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.25.
A number of research analysts have issued reports on the stock. BTIG Research reissued a “buy” rating and set a $13.00 target price (up from $8.00) on shares of Vericel in a research note on Monday, March 5th. ValuEngine raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray reissued an “overweight” rating and set a $9.00 target price on shares of Vericel in a research note on Tuesday, January 2nd. BidaskClub raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 7th. Finally, Leerink Swann initiated coverage on shares of Vericel in a research note on Wednesday. They set an “outperform” rating and a $15.00 target price for the company.
Several hedge funds have recently added to or reduced their stakes in VCEL. Goldman Sachs Group Inc. bought a new stake in shares of Vericel during the 4th quarter worth about $105,000. Bank of Montreal Can bought a new stake in shares of Vericel during the 4th quarter worth about $140,000. Wells Fargo & Company MN raised its position in shares of Vericel by 1,374.2% during the 4th quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after buying an additional 27,992 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Vericel during the 3rd quarter worth about $235,000. Finally, Bank of New York Mellon Corp raised its position in shares of Vericel by 35.2% during the 4th quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after buying an additional 11,509 shares in the last quarter. Institutional investors own 37.22% of the company’s stock.
Vericel (NASDAQ:VCEL) last posted its earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $23.35 million during the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. research analysts expect that Vericel will post -0.24 earnings per share for the current year.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.